Literature DB >> 32445085

The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease.

Giacomo Monzio Compagnoni1,2,3, Alessio Di Fonzo4, Stefania Corti4,5, Giacomo P Comi4,5, Nereo Bresolin4,5, Eliezer Masliah6.   

Abstract

Although the pathogenesis of neurodegenerative diseases is still widely unclear, various mechanisms have been proposed and several pieces of evidence are supportive for an important role of mitochondrial dysfunction. The present review provides a comprehensive and up-to-date overview about the role of mitochondria in the two most common neurodegenerative disorders: Alzheimer's disease (AD) and Parkinson's disease (PD). Mitochondrial involvement in AD is supported by clinical features like reduced glucose and oxygen brain metabolism and by numerous microscopic and molecular findings, including altered mitochondrial morphology, impaired respiratory chain function, and altered mitochondrial DNA. Furthermore, amyloid pathology and mitochondrial dysfunction seem to be bi-directionally correlated. Mitochondria have an even more remarkable role in PD. Several hints show that respiratory chain activity, in particular complex I, is impaired in the disease. Mitochondrial DNA alterations, involving deletions, point mutations, depletion, and altered maintenance, have been described. Mutations in genes directly implicated in mitochondrial functioning (like Parkin and PINK1) are responsible for rare genetic forms of the disease. A close connection between alpha-synuclein accumulation and mitochondrial dysfunction has been observed. Finally, mitochondria are involved also in atypical parkinsonisms, in particular multiple system atrophy. The available knowledge is still not sufficient to clearly state whether mitochondrial dysfunction plays a primary role in the very initial stages of these diseases or is secondary to other phenomena. However, the presented data strongly support the hypothesis that whatever the initial cause of neurodegeneration is, mitochondrial impairment has a critical role in maintaining and fostering the neurodegenerative process.

Entities:  

Keywords:  Alzheimer’s disease; Mitochondria; Neurodegeneration; Parkinson’s disease; Pathogenesis

Mesh:

Substances:

Year:  2020        PMID: 32445085      PMCID: PMC9047992          DOI: 10.1007/s12035-020-01926-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  303 in total

1.  Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence.

Authors:  S Ikebe; M Tanaka; K Ohno; W Sato; K Hattori; T Kondo; Y Mizuno; T Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1990-08-16       Impact factor: 3.575

2.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

3.  Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease.

Authors:  F Cardellach; M J Martí; J Fernández-Solá; C Marín; J B Hoek; E Tolosa; A Urbano-Márquez
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

4.  A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency.

Authors:  Catarina Quinzii; Ali Naini; Leonardo Salviati; Eva Trevisson; Placido Navas; Salvatore Dimauro; Michio Hirano
Journal:  Am J Hum Genet       Date:  2005-12-22       Impact factor: 11.025

Review 5.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

6.  Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease.

Authors:  H Yoshino; Y Nakagawa-Hattori; T Kondo; Y Mizuno
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1992

Review 7.  Mitochondria in Huntington's disease.

Authors:  Maria Damiano; Laurie Galvan; Nicole Déglon; Emmanuel Brouillet
Journal:  Biochim Biophys Acta       Date:  2009-08-11

8.  Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.

Authors:  Latha Devi; Vijayendran Raghavendran; Badanavalu M Prabhu; Narayan G Avadhani; Hindupur K Anandatheerthavarada
Journal:  J Biol Chem       Date:  2008-02-01       Impact factor: 5.157

9.  Positron emission tomography in the study of aging and senile dementia.

Authors:  S H Ferris; M J de Leon; A P Wolf; T Farkas; D R Christman; B Reisberg; J S Fowler; R Macgregor; A Goldman; A E George; S Rampal
Journal:  Neurobiol Aging       Date:  1980       Impact factor: 4.673

10.  Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains.

Authors:  Wei Wei; Michael J Keogh; Ian Wilson; Jonathan Coxhead; Sarah Ryan; Sara Rollinson; Helen Griffin; Marzena Kurzawa-Akanbi; Mauro Santibanez-Koref; Kevin Talbot; Martin R Turner; Chris-Anne McKenzie; Claire Troakes; Johannes Attems; Colin Smith; Safa Al Sarraj; Christopher M Morris; Olaf Ansorge; Stuart Pickering-Brown; James W Ironside; Patrick F Chinnery
Journal:  Acta Neuropathol Commun       Date:  2017-02-02       Impact factor: 7.801

View more
  44 in total

1.  Ratiometric Imaging of Mitochondrial Hydrogen Peroxide in Aβ42-Mediated Neurotoxicity.

Authors:  Xinyu Li; Yiyu Zhang; Hui-Wang Ai
Journal:  ACS Sens       Date:  2022-02-28       Impact factor: 7.711

2.  Mitochondrial DNA and Alzheimer's disease: a first case-control study of the Tunisian population.

Authors:  Nesrine Ben Salem; Sami Boussetta; Itziar de Rojas; Sonia Moreno-Grau; Laura Montrreal; Narjes Mokni; Imene Mahmoud; Samia Younes; Nizar Daouassi; Mahbouba Frih-Ayed; Afef Hammami; Amel Ben Ammar Elgaaied; Agustín Ruiz; Lotfi Cherni
Journal:  Mol Biol Rep       Date:  2021-12-01       Impact factor: 2.316

3.  Endoplasmic reticulum stress induces mitochondrial dysfunction but not mitochondrial unfolded protein response in SH-SY5Y cells.

Authors:  Andrea Evinova; Zuzana Hatokova; Zuzana Tatarkova; Maria Brodnanova; Katarina Dibdiakova; Peter Racay
Journal:  Mol Cell Biochem       Date:  2022-01-31       Impact factor: 3.396

Review 4.  Targeting Mitochondria as a Therapeutic Approach for Parkinson's Disease.

Authors:  Maryam Abrishamdar; Maryam Sadat Jalali; Yaghoob Farbood
Journal:  Cell Mol Neurobiol       Date:  2022-08-11       Impact factor: 4.231

Review 5.  The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health.

Authors:  Maximillian Taro William Lee; William Mahy; Mark David Rackham
Journal:  RSC Med Chem       Date:  2021-06-04

6.  Mitochondrial Dysregulation and the Influence in Neurodegenerative Diseases.

Authors:  Giuliana S Zuccoli; Victor Corasolla Carregari
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 7.  Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.

Authors:  Erin T Williams; Xi Chen; P Anthony Otero; Darren J Moore
Journal:  Neurobiol Dis       Date:  2022-05-16       Impact factor: 7.046

8.  Central nervous system (CNS) transcriptomic correlates of human immunodeficiency virus (HIV) brain RNA load in HIV-infected individuals.

Authors:  Pietro Paolo Sanna; Yu Fu; Eliezer Masliah; Celine Lefebvre; Vez Repunte-Canonigo
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.996

9.  Donepezil Protects Against Doxorubicin-Induced Chemobrain in Rats via Attenuation of Inflammation and Oxidative Stress Without Interfering With Doxorubicin Efficacy.

Authors:  Benjamin Ongnok; Thawatchai Khuanjing; Titikorn Chunchai; Patcharapong Pantiya; Sasiwan Kerdphoo; Busarin Arunsak; Wichwara Nawara; Thidarat Jaiwongkam; Nattayaporn Apaijai; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Neurotherapeutics       Date:  2021-07-26       Impact factor: 6.088

10.  AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma.

Authors:  Nicolas Belforte; Jessica Agostinone; Luis Alarcon-Martinez; Deborah Villafranca-Baughman; Florence Dotigny; Jorge L Cueva Vargas; Adriana Di Polo
Journal:  Mol Neurodegener       Date:  2021-06-29       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.